Skip to content
value.today
TELA Bio, Inc. logo

TELA Bio, Inc.

TELA
$52 Mmarket cap on Oct 6, 2026-69.0% since Jan 2024
Compare
World rank
#21,183
Revenue
$80 M
For year ending December-2025
Net income
$-39 M
-48.4% margin
SEC filing
Employees
218
As of December 31, 2025
SEC filing

TELA Bio, Inc. in brief

TELA Bio, Inc. is a listed company in the Medical Equipment industry, based in Malvern, Pennsylvania, USA. It was founded in 2012. Its market value was $52 M on 6 October 2026, which makes it the 21,183rd largest listed company in the world and the 3,843rd largest in the USA on this site. In the year to December 2025 it had sales of $80 M and a net loss of $39 M. It employs about 218 people and Heather C. Getz is its chief executive. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol TELA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About TELA Bio, Inc.

We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.

From the company's annual report filed with the US SEC: read the report

TELA Bio, Inc. timeline

4 events, 2012–2025
  1. 2012
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2019
  5. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 8 November 2019; shares registered for exchange trading on 7 November 2019.
  6. 2025
  7. 💰
    Record revenue of $80 million
    FY2025, the highest of the 8 years on record.

Events of TELA Bio, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$63 M$125 M$188 M$251 M2020202120222023202420252026

World rank over time

▼ down 4,037 places since 2020
2020-01-01: #17221#17,22120202021-01-01: #15159#15,15920212022-01-07: #19624#19,62420222022-12-25: #17601#17,60120222023-07-30: #17245#17,24520232024-01-05: #18889#18,88920242026-03-08: #11373#11,37320262026-08-01: #20921#20,92120262026-10-06: #21258#21,2582026

Rank in USA: #3,455 (Jan 2020) · #3,176 (Jan 2021) · #3,947 (Jan 2022) · #3,596 (Dec 2022) · #3,473 (Jul 2023) · #3,379 (Jan 2024) · #2,213 (Mar 2026) · #3,878 (Aug 2026) · #3,824 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.7×
Price / book
8.2×
Free cash flow yield
-55.7%
Net margin (TTM)
-53.6%
Operating margin
-42.1%
Return on equity
-663.7%
Liabilities / assets
92.2%
Net debt
$5M
Revenue growth
+15.8%
R&D / revenue
11.5%
Revenue per employee
$368 K
Profit per employee
$-178 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $8M, net income $-21M$8MFY18Fiscal year ending Dec 2019: revenue $15M, net income $-22M$15MFY19Fiscal year ending Dec 2020: revenue $18M, net income $-29M$18MFY20Fiscal year ending Dec 2021: revenue $29M, net income $-33M$29MFY21Fiscal year ending Dec 2022: revenue $41M, net income $-44M$41MFY22Fiscal year ending Dec 2023: revenue $58M, net income $-47M$58MFY23Fiscal year ending Dec 2024: revenue $69M, net income $-38M$69MFY24Fiscal year ending Dec 2025: revenue $80M, net income $-39M$80MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$80M+15.8%$-34M$-39M-48.4%
Dec 2024$69M+18.6%$-34M$-38M-54.6%
Dec 2023$58M+41.1%$-44M$-47M-79.8%
Dec 2022$41M+40.6%$-39M$-44M-107.0%
Dec 2021$29M+61.8%$-29M$-33M-113.0%
Dec 2020$18M+17.9%$-25M$-29M-158.1%
Dec 2019$15M+86.8%$-19M$-22M-145.1%
Dec 2018$8M—$-18M$-21M-255.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-28M$0M$-29M$-0.83—
Dec 2024$-42M$1M$-43M$-1.33—
Dec 2023$-41M$1M$-41M$-2.04—
Dec 2022$-41M$1M$-42M$-2.72—
Dec 2021$-30M$1M$-31M$-2.30—
Dec 2020$-24M$0M$-25M$-2.23—
Dec 2019$-26M$0M$-26M$-17.10—
Dec 2018$-20M$0M$-20M$-101.41—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$78M
Net income, trailing 12 months
$-42M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $18M, net income $-9M$18MDec ’24Three months to Mar 2025: revenue $19M, net income $-11M$19MMar ’25Three months to Jun 2025: revenue $20M, net income $-10M$20MJun ’25Three months to Sep 2025: revenue $21M, net income $-9M$21MSep ’25Three months to Dec 2025 (from the annual report): revenue $21M, net income $-9M$21MDec ’25Three months to Mar 2026: revenue $19M, net income $-12M$19MMar ’26Three months to Jun 2026: revenue $19M, net income $-11M$19MJun ’26Three months to Sep 2026: revenue $19M, net income $-9M$19MSep ’26

Latest quarter to Sep 2026: revenue $19M (-8.4% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of TELA Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$80 M
Operating income
$-34 M
Net income
$-39 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$81 M
Total liabilities
$75 M
Total equity
$6 M

As of December-2025

Top 48 institutional investors in TELA Bio, Inc.#

As of Sep 30, 2026
48 institutions held 26.3 M shares (about 58.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 52.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in TELA Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Essex Woodlands Management, Inc.7,714,7090 (0.00%)17.07%$9 MNov 6, 2026
2Nantahala Capital Management, LLC6,545,596-5,242,632 (-44.47%)14.49%$8 MNov 13, 2026
3Silverarc Capital Management, LLC2,137,2010 (0.00%)4.73%$2 MNov 12, 2026
4Perkins Capital Management Inc2,082,391+707,349 (+51.44%)4.61%$2 MNov 2, 2026
5Vanguard Capital Management LLC1,568,2180 (0.00%)3.47%$2 MNov 13, 2026
6DAFNA Capital Management LLC1,441,0290 (0.00%)3.19%$2 MNov 16, 2026
7Up Strategic Wealth Investment Advisors LLC641,556+541,668 (+542.28%)1.42%$1 MNov 12, 2026
8Sio Capital Management, LLC636,3000 (0.00%)1.41%$1 MNov 16, 2026
9WealthTrust Axiom LLC550,128+92,394 (+20.19%)1.22%$1 MNov 10, 2026
10Geode Capital Management, LLC412,662+23,439 (+6.02%)0.91%$0 MNov 6, 2026
11White Pine Capital LLC405,664New0.90%$0 MNov 9, 2026
12BlackRock, Inc.374,5160 (0.00%)0.83%$0 MNov 13, 2026
13Landscape Capital Management, L.L.C.307,645New0.68%$0 MNov 10, 2026
14Vanguard Fiduciary Trust Co213,1380 (0.00%)0.47%$0 MNov 13, 2026
15HRT Financial LP126,162New0.28%$0 MNov 13, 2026
16Marshall Wace, LLP122,237New0.27%$0 MNov 13, 2026
17Citadel Advisors LLC104,467New0.23%$0 MNov 16, 2026
18Wavvest Wealth LLC83,524—0.18%$0 MOct 21, 2026
19Jane Street Group, LLC81,737+32,492 (+65.98%)0.18%$0 MNov 12, 2026
20Northern Trust Corp74,7900 (0.00%)0.17%$0 MNov 16, 2026
21Morgan Stanley70,000+69,963 (+189089.19%)0.15%$0 MNov 13, 2026
22Raymond James Financial Inc67,7000 (0.00%)0.15%$0 MNov 12, 2026
23State Street Corp63,3830 (0.00%)0.14%$0 MNov 12, 2026
24Ducere Wealth Management LLC57,766+6,766 (+13.27%)0.13%$0 MNov 13, 2026
25PNC Financial Services Group, Inc.53,6120 (0.00%)0.12%$0 MNov 6, 2026
Show all 48: investors 26 to 48
Institutional investors 26 to 48 in TELA Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Destiny Wealth Partners, LLC52,5000 (0.00%)0.12%$0 MNov 5, 2026
27Atom Investors LP35,891+20,418 (+131.96%)0.08%$0 MNov 16, 2026
28StoneX Group Inc.30,000New0.07%$0 MNov 3, 2026
29Rollins Financial Advisors, LLC28,735New0.06%$0 MNov 10, 2026
30Mercer Global Advisors Inc /adv25,988+11,160 (+75.26%)0.06%$0 MNov 16, 2026
31Susquehanna International Group, LLP25,133New0.06%$0 MNov 16, 2026
32Great Valley Advisor Group, Inc.23,602+4,000 (+20.41%)0.05%$0 MNov 9, 2026
33TD Waterhouse Canada Inc.23,0000 (0.00%)0.05%$0 MOct 16, 2026
34Primoris Wealth Advisors, LLC20,3000 (0.00%)0.04%$0 MOct 28, 2026
35XTX Topco Ltd19,226-10,332 (-34.96%)0.04%$0 MNov 16, 2026
36J.W. Cole Advisors, Inc.16,2500 (0.00%)0.04%$0 MNov 5, 2026
37UBS Group AG15,756-17,710 (-52.92%)0.03%$0 MNov 10, 2026
38HighTower Advisors, LLC11,2000 (0.00%)0.02%$0 MNov 10, 2026
39Vanguard Global Advisers, LLC4,6040 (0.00%)0.01%$0 MNov 13, 2026
40Wells Fargo & Company/mn4,317+117 (+2.79%)0.01%$0 MNov 16, 2026
41Citigroup Inc3,039+1,265 (+71.31%)0.01%$0 MNov 4, 2026
42Jpmorgan Chase & Co1,089+1,050 (+2692.31%)0.00%$0 MNov 12, 2026
43Steward Partners Investment Advisory, LLC995-996 (-50.03%)0.00%$0 MNov 13, 2026
44Simplex Trading, LLC644-632 (-49.53%)0.00%$0 MNov 4, 2026
45SBI Securities Co., Ltd.3010 (0.00%)0.00%$0 MOct 22, 2026
46BNP Paribas Financial Markets2100 (0.00%)0.00%$0 MNov 12, 2026
47Royal Bank Of Canada61+2 (+3.39%)0.00%$0 MNov 16, 2026
48Barclays PLC6-202 (-97.12%)0.00%$0 MNov 6, 2026

Mutual funds holding TELA Bio, Inc.#

8 funds hold shares worth $2 M (about 5.8% of the company). Since their previous reports 4 added shares and 4 sold.
Mutual funds holding TELA Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.15 M$1 M3.4%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.389,470$0 M1.2%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC216,620$0 M0.65%<0.01%+26%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC66,813$0 M0.20%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC55,409$0 M0.17%<0.01%+33%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.29,070$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC18,634$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC230$0 M<0.01%<0.01%+7.5%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 8 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at TELA Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$186 K
6 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$186 K
open market only
Insiders on file
37
since
$4.0 M-$1.8 M$0Nov 2023: bought $95 K (2 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $15 K (1 trades), sold $0 (0 trades)DecJun 2024: bought $0 (0 trades), sold $1.8 M (1 trades)JunJul 2024: bought $0 (0 trades), sold $230 K (2 trades)JulOct 2024: bought $410 K (4 trades), sold $0 (0 trades)OctNov 2025: bought $4.0 M (1 trades), sold $0 (0 trades)NovAug 2026: bought $19 K (2 trades), sold $0 (0 trades)AugSep 2026: bought $168 K (4 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
TELA Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed William J. PlovanicDirectorGrant or award+16,089$1.010$16 K60,619Form 4
filed Joseph H. CapperDirectorGrant or award+19,801$1.010$20 K199,628Form 4
filed Joseph H. CapperDirectorBuy+25,000$1.220$31 K179,827Form 4
filed Joseph H. CapperDirectorBuy+50,000$1.170$59 K154,827Form 4
filed Joseph H. CapperDirectorBuy+50,000$1.060$53 K104,827Form 4
filed Joseph H. CapperDirectorBuy+25,000$1.020$26 K54,827Form 4
filed Heather C. GetzChief Executive Officer, DirectorBuy+12,500$0.660$8 K532,500Form 4
filed Heather C. GetzChief Executive Officer, DirectorBuy+15,000$0.700$11 K520,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: TELA Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
579,565
1.3% of shares · 5.07 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split

Fails to deliver

  • : 2,444 shares at $1.14
  • : 7,271 shares at $1.30
  • : 2,084 shares at $1.30
  • : 16,788 shares at $1.25
  • : 6,087 shares at $1.18

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

TELA Bio, Inc. scorecard#

Passes 6 of the 21 checks that could be worked out: strongest in growth (3 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 6, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median8.2×Price to book 8.2× against Healthcare's median of 3.1×.
    • ✓Price to sales below its peers' median0.7×Price to sales 0.7× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-55.7%Free cash flow is -55.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 6
    • ✓Revenue grew in the newest year15.8%Revenue up 15.8% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years24.7%24.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median24.7%24.7% a year against Medical Equipment's median of 24.7% (5 companies).
    • ✗Earnings per share grew in the newest year-0.83 vs -1.33Diluted EPS -0.83 in fiscal 2025 against -1.33 the year before (report's currency).
    • ✗Net income higher than five years earlier-$39 M-$39 M in fiscal 2025 against -$29 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-42.0%-42.0% against Medical Equipment's median of -38.5% (8 companies).
    • ✗Return on equity above 15%-223.3%-223.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-42.0%-42.0% in fiscal 2025 against -94.2% in 2022.
  • Financial health1 of 4
    • ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.20 at the end of fiscal 2025.
    • ✗Debt below equity8.8×Debt to equity 8.82 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-5.96Z-score -5.96 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year64.6%Diluted shares up 64.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Equipment, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from TELA Bio, Inc.'s statements, beside the median of Medical Equipment.

TELA Bio, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-42.1%-38.5%
Net margin-48.4%-44.9%
Return on equity-223.4%-94.5%
Revenue growth, 3 years a year24.7%24.7%
Revenue growth15.8%15.6%
Debt to equity8.82×—

3of 9on the Piotroski tests of financial strength

  • Net loss of $39 million, the 9th loss-making year in a row.
  • Free cash flow was negative: -$29 million.
  • The share count rose 64.6% in the year.
  • Revenue has grown 8 years in a row.

TELA Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

TELA Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue806958412918158.34.2
Gross profit5446402719119.32.92.5
Research and development9.28.89.68.96.74.34.24.35.8
Selling and marketing63656043292218148.7
General and administrative1615151412106.24.95.0
Operating expenses888884664837282119
Operating income−34−34−44−39−29−25−19−18−17
Interest expense and finance costs5.25.35.24.13.63.63.61.84.6
Other non-operating income (expense)−4.8−3.9−2.6−5.3−3.8−3.5−3.3−3.3−4.4
Income before tax−39−38−47−44—————
Income tax0.2−0.1———————
Net income including minority interests−39−38−47−44−33−29−22——
Net income attributable to shareholders−39−38−47−44−33−29−22−21−21
Earnings per share, basic-0.83-1.33-2.04-2.72-2.30-2.23-17.10-101.41—
Earnings per share, diluted-0.83-1.33-2.04-2.72-2.30-2.23-17.10-101.41—
Shares, weighted average (basic)4729231614131.8——
Shares, weighted average (diluted)4729231614131.80.30.3
Balance sheet
Cash and cash equivalents515347424474451711
Short-term investments—————09.3——
Receivables10109.76.64.22.72.81.3—
Inventory111313127.73.94.64.3—
Other current assets3.42.52.12.03.22.22.30.3—
Current assets7678726259836423—
Property, plant and equipment2.22.32.01.71.20.60.70.8—
Right-of-use (leased) assets1.51.72.01.2—————
Other intangible assets1.41.72.12.52.32.62.9——
Total assets8187786863866827—
Accounts payable2.32.11.71.52.40.73.23.4—
Current liabilities18161712116.66.79.6—
Long-term debt56414140—————
Lease liabilities (non-current)—1.5r1.71.2—————
Total liabilities7558595442373741—
Retained earnings−398−359−321−274−230−197−168−138—
Shareholders' equity6.3281914204931−138−108
Total liabilities and equity8187786863866827—
Shares outstanding453924191514110.3—
Cash-flow statement
Share-based compensation3.84.45.04.03.72.10.50.20.2
Cash from operating activities−28−42−41−41−30−24−26−20−16
Capital expenditure−0.4−1.0−0.6−0.9−0.6−0.2−0.2−0.1−0.1
Intangible assets bought———−1.0——−2.5−1.5—
Cash from investing activities0.84.5−0.6−1.9−0.69.1−12−1.6−0.1
Debt issued———40—————
Debt repaid−42——−30———−13—
Shares issued——4634—45r———
Cash from financing activities264346410.644662726
Exchange-rate effect on cash—————0.0−0.0——
Change in cash−1.85.95.0−1.9−3029285.99.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What TELA Bio, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Single reportable segment$80 M100%

Countries and regions

  • Non-US(total)$12 M15%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where TELA Bio, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

TELA Bio, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at TELA Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Restructuring 1 · Directors and officers 9 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 11

TELA Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Delisting notice8-K
RestructuringDirectors and officers8-K
Directors and officers8-K/A
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officersResults announced8-K
Results announced8-K
Delisting notice8-K
Material agreementAgreement endedNew debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

7 private funding rounds before listing

Private share sales · funding history

Private share sales of TELA Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2019$11 MNo. 7$10 to $50 million15equitySEC
Nov 2018$2 MNo. 6$2 to $10 million8equitySEC
Oct 2017$15 MNo. 5$10 to $50 million1equitySEC
Jan 2017$7 MNo. 4$2 to $10 million16equitySEC
Oct 2014$45 MNo. 3$10 to $50 million29equitySEC
Aug 2013$6 MNo. 2$2 to $10 million16equitySEC
Dec 2012$16 MNo. 1$10 to $50 million15equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at TELA Bio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2026–2026
Latest
—
2026-08-28
TELA Bio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
TELA Bio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
20% of workforceRestructuring planSEC 8-K“The Plan will reduce the Company’s workforce by approximately 20%, from 201 full-time employees to 160 full-time employees, and is expected to be substantially completed during the…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How TELA Bio, Inc. compares in Medical Equipment

  • Market cap$52 M · higher than 29% of 8
  • Revenue$80 M · higher than 50% of 19
  • Net margin-53.6% · higher than 12% of 17
  • Revenue growth15.8% · higher than 67% of 13
  • Price / sales0.7× · lower than 67% of 7
  • Price / book8.2× · lower than 0% of 7
  • FCF yield-55.7% · higher than 0% of 7

Peer comparison · Medical Equipment

CompanyMarket capP/ENet marginRev. growth
TELA Bio, Inc.🇺🇸$52 M—-53.6%+15.8%
Avita Medical, Inc.🇺🇸$525 M—-42.6%+11.5%
Viemed Healthcare, Inc.🇺🇸$367 M23.5×5.0%+20.5%
Electromed, Inc.🇺🇸$341 M28.6×15.8%+15.3%
Profound Medical Corp.🇨🇦$240 M—-137.4%+50.8%
Streamex Corp.🇺🇸$52 M——+100.0%
IRIDEX Corporation🇺🇸$12 M—-6.9%+8.2%
Beyond Air, Inc.🇺🇸$4 M—-407.6%+107.6%
Varian Medical Systems🇺🇸$16.3 B—8.5%-1.8%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 6, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at TELA Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show TELA Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about TELA Bio, Inc.? Suggest a correction